Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2672-2679

  Brandenburg, Vincent Matthias ^a   Schlieper, Georg ^a   Heussen, Nicole ^b   Holzmann, Stefan ^c   Busch, Birgit ^a   Evenepoel, Pieter ^d   Vanholder, Raymond ^e   Meijers, Björn ^d   Meert, Natalie ^e   Fassbender, Walter J ^f   Floege, Jürgen ^a   Jahnen Dechent, Willi ^a   Ketteler, Markus ^g  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Dialysis Center Erkelenz   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Hospital zum heiligen Geist   (Germany)

^g KLINIKUM COBURG   (Germany)

Author keywords

dialysis; fetuin A; hyperphosphataemia; pleiotropic effects; sevelamer hydrochloride

Indexed keywords

ALBUMIN; ALFACALCIDOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CINACALCET; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HIPPURIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLEACETIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; SEVELAMER; UREMIC TOXIN; URIC ACID; AHSG PROTEIN, HUMAN; CHELATING AGENT; PLASMA PROTEIN; POLYAMINE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BONE DISEASE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTERVENTION STUDY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; TREATMENT DURATION; URIC ACID BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMPLICATION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; BLOOD PROTEINS; C-REACTIVE PROTEIN; CALCIUM; CARDIOVASCULAR DISEASES; CHELATING AGENTS; CHOLESTEROL, LDL; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYAMINES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 77954796215     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq053     Document Type: Article

References (32)

1. Foley RN, Parfrey PS, Samak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23
2. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579
3. Hruska KA, Mathew S, Lund R et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157
4. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-620
5. Goodman WG. The consequences of uncontrolled secondary hyper- parathyroidism and its treatment in chronic kidney disease. Semin Dial 2004; 17: 209-216
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
7. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1: 697-703
8. Galassi A, Spiegel DM, Bellasi A et al. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006; 21: 3215-3222
9. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
10. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
11. Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer-are they of clinical relevance?. Semin Dial 2008; 21: 385-389
12. Nikolov IG, Joki N, Maizel J et al. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int 2006; 70: S16-S23
13. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with se- velamer increases serum fetuin-a concentration and improves endo- thelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68
14. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
15. Clase CM, Norman GL, Beecroft ML et al. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1841-1846
16. Hermans MM, Brandenburg V Ketteler M et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72: 202-207
17. Meert N, Eloot S, Waterloos MA et al. Effective removal of protein- bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009; 24: 562-570
18. de Loor H, Bammens B, Evenepoel P et al. Gas chromatographic- mass spectrometric analysis for measurement of P-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538
19. de Loor H, Meijers BK, Meyer TW et al. Sodium octanoate to reverse indoxyl sulfate and P-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 2009; 1216: 4684-4688
20. Jahnen-Dechent W, Schafer C, Ketteler M et al. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. JMol Med 2008; 86: 379-389
21. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2- Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366
22. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin- A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
23. Takei T, Otsubo S, Uchida K et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialy- sis. Nephron Clin Pract 2008; 108: c278-c283
24. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dysli- pidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27: 361-365
25. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
26. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004; 65: 1-14
27. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
28. Vanholder R, Baurmeister U, Brunet P et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19: 863-870
29. De Smet R, Thermote F, Lameire N et al. Sevelamer hydrochloride (Renagel) absorbs the uremic compound indoxyle sulfate. J Am Soc Nephrol 2003; 14: 206A
30. Ketteler M. Kidney failure and the gut: P-cresol and the dangers from within. Kidney Int 2006; 69: 952-953
31. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-de- ficient mice. Circulation 2005; 112: 2875-2882
32. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087